

AMENDMENTS TO THE CLAIMS:

Claim 1 (Currently Amended): A process for the purification of olanzapine characterized in that said process comprises the following steps:

- a) mixing olanzapine with an organic acid in an organic solvent or a mixture of organic solvents to form an olanzapine acid addition salt,
- b) precipitating and isolating the olanzapine acid addition salt and,
- c) transforming the olanzapine acid addition salt to olanzapine, wherein the transformation step comprises the following substeps:
 - i) dissolving the acid addition salt of olanzapine in water to make a solution thereof,
 - ii) adjusting the pH of the obtained solution to about 8-10,
 - iii) contacting the adjusted pH *aqueous* solution with an organic solvent to form a separate water phase and organic solvent phase;
 - iv) extracting olanzapine from the water phase to the organic solvent phase; and
 - v) isolating olanzapine from the organic solvent phase by concentrating the organic solvent phase to cause olanzapine crystals to form therein and separating the crystals of olanzapine from the organic solvent phase;

wherein the olanzapine crystals include less than 0.05 % of piperazine 1,4-bis-4-yl-(2-methyl)-10H-thieno-[2,3-b][1,5]benzodiazepine.

Claim 2 (Previously Presented): The process according to claim 1 wherein the organic acid in step (a) is selected from the group consisting of sulfonic acids and carboxylic acids.

Claim 3 (Previously Presented): The process according to claim 2 wherein the carboxylic acid is selected from the group consisting of fumaric acid and benzoic acid.

Claim 4 (Previously Presented): The process according to claim 1 wherein the organic solvent in step (a) is selected from the group consisting of tetrahydrofuran, acetone, dimethylformamide and acetonitrile.

Claim 5 (Previously Presented): The process according to claim 1 wherein the mixture of organic solvents in step (a) is a mixture of tetrahydrofuran with at least one polar solvent.

Claim 6 (Previously Presented): The process according to claim 5 wherein said polar solvent is selected from the group consisting of dimethylformamide, dimethylacetamide, N-

U.S. Application No. 10/598,816

methylpyrrolidone, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, 1,3-dimethyl-2-imidazolidinone, tetramethylurea, dimethyl sulfoxide, sulfolane, acetone and acetonitrile.

Claims 7 – 34 (Cancelled)

Claim 35 (Previously Presented): Olanzapine prepared according to the processes disclosed in claim 1 characterized in that the N-desmethylolanzapine content, if any, in the final product of olanzapine is less than 0.1 %.

Claim 36 (Previously Presented): Olanzapine prepared according to the processes disclosed in claim 1 that contains less than 0.05 % of piperazine 1,4-bis-4-yl-(2-methyl)-10H-thieno-[2,3-b][1,5]benzodiazepine.

Claims 37-43 (Cancelled)